{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Death due to cardiovascular while on study (heart failure, myocardial infarction, fatal arrhythmia).","groups":[{"description":"* Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.\n* Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.\n* Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.\n* In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin..","id":"OG000","title":"Arm 1: Doxorubicin and Upfront Dexrazoxane"},{"description":"* Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.\n* Starting with cycle 5, standard of care dexrazoxane (75 mg/m2) will be given for 4 cycles.\n* The last 10 patients enrolled after completion of enrollment to Arm 1 will be enrolled to Arm 2.","id":"OG001","title":"Arm 2: Control (Doxorubicin and Standard of Care Dexrazoxane)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Cardiac-related Mortality","type":"SECONDARY","unitOfMeasure":"Participants"}